AlkermesALKS
ALKS
About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Employees: 1,800
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
133% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 7 (+4) [Q4]
72% more call options, than puts
Call options by funds: $7.15M | Put options by funds: $4.15M
23% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 44
1% more funds holding
Funds holding: 334 [Q3] → 338 (+4) [Q4]
3% less capital invested
Capital invested by funds: $4.94B [Q3] → $4.81B (-$136M) [Q4]
9% less repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 126
8.48% less ownership
Funds ownership: 107.29% [Q3] → 98.81% (-8.48%) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
11%
upside
Avg. target
$41
41%
upside
High target
$52
81%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
UBS Ashwani Verma 25% 1-year accuracy 5 / 20 met price target | 15%upside $33 | Neutral Maintained | 28 Apr 2025 |
Deutsche Bank David Hoang 12% 1-year accuracy 2 / 17 met price target | 81%upside $52 | Buy Maintained | 27 Mar 2025 |
RBC Capital Leonid Timashev 21% 1-year accuracy 9 / 42 met price target | 39%upside $40 | Sector Perform Initiated | 13 Mar 2025 |
Goldman Sachs Chris Shibutani 25% 1-year accuracy 3 / 12 met price target | 11%upside $32 | Buy Maintained | 14 Feb 2025 |
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target | 60%upside $46 | Neutral Reiterated | 13 Feb 2025 |
Financial journalist opinion
Based on 7 articles about ALKS published over the past 30 days
Neutral
PRNewsWire
14 hours ago
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives – DUBLIN , April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64 who self-identify as having been diagnosed with alcohol use disorder (AUD) by a healthcare provider. The survey showed that the path to AUD diagnosis can be challenging and often driven by negative consequences, but treatment may positively impact people living with AUD.
Negative
Zacks Investment Research
6 days ago
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
1 week ago
Alkermes to Report First Quarter Financial Results on May 1, 2025
DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Neutral
PRNewsWire
4 weeks ago
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m.
Positive
Zacks Investment Research
4 weeks ago
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
Neutral
PRNewsWire
4 weeks ago
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
DUBLIN , April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness.
Neutral
PRNewsWire
1 month ago
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life – – 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thinking About Treatment Effect – DUBLIN , March 27, 2025 /PRNewswire/ -- People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly completed survey designed to better understand the perspectives of healthcare providers on patients' treatment experiences and outcomes indicated that providers often prioritize approaches that support long-term symptom control, treatment consistency and quality of life considerations.
Neutral
Zacks Investment Research
1 month ago
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
Positive
Investors Business Daily
1 month ago
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait
GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily.
Neutral
Investors Business Daily
1 month ago
Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points
On St. Patrick's Day, PDD Holdings and Aon lead five stocks near buy points that are at least a "little Irish." The post Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™